- Home
- PHAR vs EVV Comparison
PHAR vs EVV Comparison
Compare PHAR & EVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PHAR | EVV |
|---|---|---|
| Founded | 1988 | N/A |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2020 | 2003 |
Fundamental Metrics
Financial Performance| Metric | PHAR | EVV |
|---|---|---|
| Price | $18.36 | $9.51 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $38.33 | N/A |
| AVG Volume (30 Days) | 12.9K | ★ 356.3K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.04 | N/A |
| Revenue Next Year | $2.51 | N/A |
| P/E Ratio | $3,041.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.05 | $8.97 |
| 52 Week High | $21.34 | $10.41 |
Technical Indicators
Market Signals| Indicator | PHAR | EVV |
|---|---|---|
| Relative Strength Index (RSI) | 57.20 | 51.68 |
| Support Level | $16.90 | $8.97 |
| Resistance Level | $17.70 | $9.57 |
| Average True Range (ATR) | 0.64 | 0.12 |
| MACD | 0.14 | 0.04 |
| Stochastic Oscillator | 61.10 | 86.67 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.